ES2040615B1 - Procedimiento para el aislamiento y clonaje de cdnas derivados del virus c de la hepatitis. - Google Patents

Procedimiento para el aislamiento y clonaje de cdnas derivados del virus c de la hepatitis.

Info

Publication number
ES2040615B1
ES2040615B1 ES9101274A ES9101274A ES2040615B1 ES 2040615 B1 ES2040615 B1 ES 2040615B1 ES 9101274 A ES9101274 A ES 9101274A ES 9101274 A ES9101274 A ES 9101274A ES 2040615 B1 ES2040615 B1 ES 2040615B1
Authority
ES
Spain
Prior art keywords
cloning
isolation
procedure
hepatitis virus
cdnas derived
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES9101274A
Other languages
English (en)
Other versions
ES2040615A1 (es
Inventor
Nebrda Fernando Javi Bartolome
Garcia Vicente Carreno
Aguilar Inmaculada Castillo
Estevez Juan Antonio Quiroga
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to ES9101274A priority Critical patent/ES2040615B1/es
Publication of ES2040615A1 publication Critical patent/ES2040615A1/es
Application granted granted Critical
Publication of ES2040615B1 publication Critical patent/ES2040615B1/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Landscapes

  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

PROCEDIMIENTO PARA EL AISLAMIENTO Y CLONAJE DE CDNAS DERIVADOS DEL VIRUS C DE LA HEPATITIS. PROCEDIMIENTO PARA EL AISLAMIENTO Y CLONAJE DE CDNAS DERIVADOS DEL VIRUS C DE LA HEPATITIS, A PARTIR DE SUERO Y TEJIDOS HUMANOS DE PACIENTES DE ESTA INFECCION. UNA PARTE DEL SUERO SE MEZCLA CON UNA SOLUCION DE ISOTIACIANATO DE GUANIDINA, CITRATO SOCIDO, 2 MERCAPTOETANO, SARKOSYL, FENOL, UNA CANTIDAD DE TRNA Y CLOROFORMO. TRAS INCUBAR LA MEZCLA EN HIELO, SE CENTRIFUGA Y SE EXTRAE LA FASE ACUOSA CON CLOROFORMO. SE TRATA EL GENOMA VIRAL CON UN INHIBIDOR DE R-NASAS Y SE PRECIPITA CON ISOPROPANOL. LOS ACIDOS NUCLEICOS CENTRIFUGADOS SE DESNATURALEZAN POR CALOR, Y SE UTILIZAN COMO MOLDE JUNTO CON OLIGONUCLEOTIDOS SINTETICOS, PARA OBTENER EL CDNA SINTETICO. ESTE SE AMPLIFICA, SE FRACCIONA Y SE CLONAN LOS FRAGMENTOS EN EL VECTOR PCR1000, OBTENIENDOSE PLASMIDOS RECOMBINANTES, QUE SE PROPAGAN EN UNA CEPA BACTERIANA, PARAOBTENER LOS CLONES POSITIVOS.
ES9101274A 1991-05-27 1991-05-27 Procedimiento para el aislamiento y clonaje de cdnas derivados del virus c de la hepatitis. Expired - Lifetime ES2040615B1 (es)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ES9101274A ES2040615B1 (es) 1991-05-27 1991-05-27 Procedimiento para el aislamiento y clonaje de cdnas derivados del virus c de la hepatitis.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES9101274A ES2040615B1 (es) 1991-05-27 1991-05-27 Procedimiento para el aislamiento y clonaje de cdnas derivados del virus c de la hepatitis.

Publications (2)

Publication Number Publication Date
ES2040615A1 ES2040615A1 (es) 1993-10-16
ES2040615B1 true ES2040615B1 (es) 1994-05-16

Family

ID=8272499

Family Applications (1)

Application Number Title Priority Date Filing Date
ES9101274A Expired - Lifetime ES2040615B1 (es) 1991-05-27 1991-05-27 Procedimiento para el aislamiento y clonaje de cdnas derivados del virus c de la hepatitis.

Country Status (1)

Country Link
ES (1) ES2040615B1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6461815B1 (en) 1998-05-22 2002-10-08 North Carolina State University Antibacterial agents and methods of screening for the same
JP2005508306A (ja) 2001-07-23 2005-03-31 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ 哺乳類における遺伝子発現のＲＮＡｉによる阻害に関する方法および組成物
US10590418B2 (en) 2001-07-23 2020-03-17 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for RNAi mediated inhibition of gene expression in mammals

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1049686C (zh) * 1987-11-18 2000-02-23 希龙股份有限公司 非ａ和非ｂ肝炎病毒的诊断及疫苗

Also Published As

Publication number Publication date
ES2040615A1 (es) 1993-10-16

Similar Documents

Publication Publication Date Title
CN112480217B (zh) 基于SARS-CoV-2的S抗原蛋白的疫苗和组合物
CA1323851C (en) Expression of human proapolipoprotein a-i
Banerjea et al. High-level synthesis of biologically active reovirus protein σ1 in a mammalian expression vector system
Bardina et al. Mengovirus-induced rearrangement of the nuclear pore complex: hijacking cellular phosphorylation machinery
BR0016145A (pt) Clones infecciosos
Dong et al. CRISPR/Cas12a mediated genome editing enhances Bombyx mori resistance to BmNPV
Zhang et al. Identification of a natural mutant of HBV X protein truncated 27 amino acids at the COOH terminal and its effect on liver cell proliferation 1
ES2040615B1 (es) Procedimiento para el aislamiento y clonaje de cdnas derivados del virus c de la hepatitis.
Gong et al. Identification of the resistance of a novel molecule heat shock protein 90α (HSP90α) in Microtus fortis to Schistosoma japonicum infection
CN112353939B (zh) Gtpbp4蛋白作为免疫抑制剂的应用及敲低或过表达gtpbp4细胞系的构建
Zhou et al. Efficient silencing of hepatitis B virus S gene through CRISPR‐mediated base editing
Detjen et al. Poliovirus single-stranded RNA and double-stranded RNA: differential infectivity in enucleate cells
EP4371564A3 (en) Design of bacteriophage-based artificial viruses for human genome remodeling
AR124736A1 (es) EFECTO SINÉRGICO DE SMN1 Y miR-23a EN EL TRATAMIENTO DE LA ATROFIA MUSCULAR ESPINAL
Moradpour et al. Tightly regulated expression of the entire hepatitis C virus structural region in continuous human cell lines
SI8510058A8 (en) Process for insulation of poultry egg's cystatine from egg-white
Hu et al. DNA double-strand breaks, potential targets for HBV integration
HU202581B (en) Process for producing valuable protein materials with utilizing recombinant dns of bomby mori polyhedrosis virus
Mathur et al. Expression of L protein of vesicular stomatitis virus Indiana serotype from recombinant baculovirus in insect cells: requirement of a host factor (s) for its biological activity in vitro
Tseng et al. Hepatopancreas and ovary are sites of vitellogenin synthesis as determined from partial cDNA encoding of vitellogenin in the marine shrimp, Penaeus vannamei
CN114989266B (zh) 一种非洲猪瘟病毒pA104R蛋白免疫抑制相关氨基酸位点及其应用
WO2015042187A1 (en) Treatment of hepatitis d virus infections by redirection of t cells
Wang et al. Characterization of a J domain gene of Spodoptera litura multicapsid nucleopolyhedrovirus
Nüesch et al. Proteins specifically binding to the 3′ untranslated region of hepatitis A virus RNA in persistently infected cells
EP1642981B1 (en) RECOMBINANT GENE MEDICINE OF ADENOVIRUS VECTOR AND GENE p53 FOR TREATING PROLIFERATIVE DISEASES

Legal Events

Date Code Title Description
FA2A Application withdrawn

Effective date: 19950211